Talk:Drug Price Competition and Patent Term Restoration Act

United States: Government Low‑importance

	United States portal This article is within the scope of WikiProject United States, a collaborative effort to improve the coverage of topics relating to the United States of America on Wikipedia. If you would like to participate, please visit the project page, where you can join the ongoing discussions. Template Usage Articles Requested! Become a Member Project Talk Alerts United StatesWikipedia:WikiProject United StatesTemplate:WikiProject United StatesUnited States articles
Low	This article has been rated as Low-importance on the project's importance scale.
	This article is supported by WikiProject U.S. Government (assessed as Low-importance).

Law

	Law portal This article is within the scope of WikiProject Law, an attempt at providing a comprehensive, standardised, pan-jurisdictional and up-to-date resource for the legal field and the subjects encompassed by it.LawWikipedia:WikiProject LawTemplate:WikiProject Lawlaw articles
???	This article has not yet received a rating on the project's importance scale.

Tip: Anchors are case-sensitive in most browsers.

This article links to one or more target anchors that no longer exist.

[[Patent#Patent invalidity|invalid]]

Please help fix the broken anchors. You can remove this template after fixing the problems. | Reporting errors

Untitled

Generic drugs need to be within 20% of specifications of brand name. So, generic and brand names are not the same.

Neutrality

The article reads like an anti-generics opinion piece, and almost accuses the FDA of putting patients lives at risk. Some examples of suggestive language (emphasis added):

This numbers are strictly arbitrary numbers that were deemed to be sufficiently long to ...
However, the act makes many assumptions that since being proved invalid or inappropriate have caused the act to come under scrutiny.
A major assumption within ...
This could potentially lead to a forty percent differential that may not be safe or effective. It is interesting that FDA has not altered this particular aspect of the regulation given the advances in modern pharmaceutics, which would allow these standards to be tightened.
It may seem like a good assumption, but that there is more leniency in the approval process for generics that could be symbolic of some bias within the FDA.

Most of it is based on one source and the "potential revisions" section seems to contain only revisions that would benefit patent-holders. Nothing that addresses the dangers to patients mentioned before. DS Belgium (talk) 20:48, 21 September 2011 (UTC)[reply]

Four conditions

I'm not knowledgeable enough about the Act to make the change myself, but the bit about the paragraph I, II, III, and IV certifications is worded misleadingly. "It also sets out the condition [sic] that must be met when someone files an ANDA. The first is [...]. The second is [...]. The third is [...]. Lastly, it is required that [...]." This makes it sound like all four conditions must be satisfied, but this article indicates that only one—any one—of said conditions need be satisfied. Istaro (talk) 12:16, 2 August 2012 (UTC)[reply]

Proposed merge

I propose to merge Approved Drug Products with Therapeutic Equivalence Evaluations into this article as its own subsection. The Orange Book is just a creation of this statute. BD2412 T 17:23, 25 April 2020 (UTC)[reply]

Oppose, given that the orange book has sufficient notability to warrant independent peer-reviewed coverage (see the two articles I've just added as further reading). Klbrain (talk) 21:03, 24 October 2020 (UTC)[reply]

Closing, given the uncontested objection and no support over more than 10 months. Klbrain (talk) 12:05, 13 March 2021 (UTC)[reply]

Wikipedia Ambassador Program course assignment

This article is the subject of an educational assignment at New York University supported by the Wikipedia Ambassador Program during the 2011 Spring term. Further details are available on the course page.

The above message was substituted from {{WAP assignment}} by PrimeBOT (talk) on 16:24, 2 January 2023 (UTC)[reply]